Patents by Inventor Hiroki Shirai

Hiroki Shirai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11914015
    Abstract: Provided is a magnetic resonance imaging apparatus with no occurrence of artifacts, even after noise removal by applying Wavelet transform to a zero-fill reconstructed image. Nuclear magnetic resonance signals acquired by the magnetic resonance imaging apparatus are processed to perform reconstruction with a reconstruction matrix extended by zero-filling an acquisition matrix, and then a zero-fill reconstructed image is produced. This reconstructed image is subjected to an iterative operation combining the Wavelet transform and L1 norm minimization to remove noise. Before the noise removal, a pre-processing is performed to change the reconstruction matrix size so that an artifact does not occur in the image after noise removal, an artifact portion appears outside the reconstruction matrix after the noise removal, or cutting out is performed so that no artifact appears after the noise removal. The matrix size is restored to its original size in the post-processing after the noise removal.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 27, 2024
    Assignee: FUJIFILM HEALTHCARE CORPORATION
    Inventors: Hiroki Shoji, Toru Shirai, Shinji Kurokawa
  • Publication number: 20230303658
    Abstract: The present invention provides a polypeptide comprising a modified Fc region of an IgG, and a modified Fcy receptor that binds specifically to the polypeptide, and methods for treating or preventing a disease or a disorder in a patient using immunotherapy.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Inventors: Ryuichi Moriya, Hiroki Shirai, Shinji Soga, Naoko Shimada, David William Russell
  • Patent number: 11679166
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 20, 2023
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 11667724
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 6, 2023
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Publication number: 20220096653
    Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 31, 2022
    Inventors: Michinori Akaiwa, Junya Ishida, Hiroki Toya, Nobuyuki Shiraishi, Toru Asano, Tomoaki Yoshikawa, Yorikata Sano, Hitoshi Doihara, Hiroki Shirai, Kazunori Hirayama
  • Publication number: 20210340276
    Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 4, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Toru ASANO, Yorikata SANO, Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Michinori AKAIWA, Hiroyoshi YAMADA, Nobuyuki SHIRAISHI
  • Publication number: 20200261603
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 12, 2019
    Publication date: August 20, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200171174
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 4, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200123270
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: July 6, 2018
    Publication date: April 23, 2020
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Patent number: 10517966
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 31, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 10507251
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: December 17, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Publication number: 20190307906
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 10, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20190269804
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 8946800
    Abstract: To provide a semiconductor device featuring reduced variation in capacitor characteristics. In the semiconductor device, a protective layer is provided at the periphery of the upper end portion of a recess (hole). This protective layer has a dielectric constant higher than that of an insulating layer placed in the same layer as the protective layer and configuring a multilayer wiring layer placed in a logic circuit region.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: February 3, 2015
    Assignee: Renesas Electronics Corporation
    Inventors: Ippei Kume, Kenichiro Hijioka, Naoya Inoue, Hiroyuki Kunishima, Manabu Iguchi, Hiroki Shirai
  • Patent number: 8648441
    Abstract: A semiconductor device has a substrate; a multi-layered interconnect formed on the substrate, and having a plurality of interconnect layers, each of which being configured by an interconnect and an insulating layer, stacked therein; a memory circuit formed in a memory circuit region on the substrate in a plan view, and having a peripheral circuit and at least one capacitor element embedded in the multi-layered interconnect; and a logic circuit formed in a logic circuit region on the substrate, wherein the capacitor element is configured by a lower electrode, a capacitor insulating film, an upper electrode, an embedded electrode and an upper interconnect; the top surface of the upper interconnect, and the top surface of the interconnect configuring the logic circuit formed in the same interconnect layer with the upper interconnect, are aligned to the same plane.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: February 11, 2014
    Assignee: Renesas Electronics Corporation
    Inventors: Kenichiro Hijioka, Ippei Kume, Naoya Inoue, Hiroki Shirai, Jun Kawahara, Yoshihiro Hayashi
  • Patent number: 8507373
    Abstract: A semiconductor device having a DRAM region and a logic region embedded together therein, including a first transistor formed in a DRAM region, and having a first source/drain region containing at least a first impurity, and a second transistor formed in a logic region, and having a second source/drain region containing at least a second impurity, wherein each of the first source/drain region and the second source/drain region has a silicide layer respectively formed in the surficial portion thereof, and the first source/drain region has a junction depth which is determined by an impurity and is deeper than the junction depth of the second source/drain region.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: August 13, 2013
    Assignee: Renesas Electronics Corporation
    Inventor: Hiroki Shirai
  • Publication number: 20130056850
    Abstract: To provide a semiconductor device featuring reduced variation in capacitor characteristics. In the semiconductor device, a protective layer is provided at the periphery of the upper end portion of a recess (hole). This protective layer has a dielectric constant higher than that of an insulating layer placed in the same layer as the protective layer and configuring a multilayer wiring layer placed in a logic circuit region.
    Type: Application
    Filed: August 23, 2012
    Publication date: March 7, 2013
    Inventors: Ippei KUME, Kenichiro Hijioka, Naoya Inoue, Hiroyuki Kunishima, Manabu Iguchi, Hiroki Shirai
  • Patent number: 8299543
    Abstract: A semiconductor device, includes a substrate, an element isolating film formed in the substrate, a first element formation region isolated by the element isolating film, a second element formation region positioned adjacent to the first element formation region and isolated by the element isolating film, a first well of a second conductive type formed in a whole area of the first element formation region, a first transistor of a first conductive type formed on the first element formation region, a second transistor of the first conductive type which is formed on the first element formation region and whose threshold voltage is the same as a threshold voltage of the first transistor, a second well of the second conductive type formed in a whole area of the second element formation region, and a third transistor of the first conductive type formed on the second element formation region.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: October 30, 2012
    Assignee: Renesas Electronics Corporation
    Inventors: Takashi Sakoh, Hiroki Shirai
  • Publication number: 20120168876
    Abstract: A semiconductor device, includes a substrate, an element isolating film formed in the substrate, a first element formation region isolated by the element isolating film, a second element formation region positioned adjacent to the first element formation region and isolated by the element isolating film, a first well of a second conductive type formed in a whole area of the first element formation region, a first transistor of a first conductive type formed on the first element formation region, a second transistor of the first conductive type which is formed on the first element formation region and whose threshold voltage is the same as a threshold voltage of the first transistor, a second well of the second conductive type formed in a whole area of the second element formation region, and a third transistor of the first conductive type formed on the second element formation region.
    Type: Application
    Filed: March 9, 2012
    Publication date: July 5, 2012
    Applicant: RENESAS ELECTRONICS CORPORATION
    Inventors: Takashi SAKOH, Hiroki SHIRAI
  • Patent number: 8143119
    Abstract: A first transistor and a second transistor are formed in a first element formation region, and a third transistor is formed in a second element formation region. The three transistors are of the same conductive type, and the first transistor and the second transistor have the same threshold voltage. A first well is formed in the first element formation region by use of a first mask pattern, and a second well is formed in the second element formation region by use of a second mask pattern. A channel region of the first transistor and a channel region of the second transistor have a shape which is line-symmetrical with respect to a reference line. The first mask pattern has a shape which is line-symmetrical with respect to the reference line.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: March 27, 2012
    Assignee: Renesas Electronics Corporation
    Inventors: Takashi Sakoh, Hiroki Shirai